Shu Zhang

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

Li Liu, Patrick A. Mayes, Stephen D. Eastman et al. · Clinical Cancer Research · 2015 · 440 citations

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

Richard G. Wunderink, Evangelos J. Giamarellos‐Bourboulis, Galia Rahav et al. · Infectious Diseases and Therapy · 2018 · 418 citations · Full text

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Won Jin Ho, Qingfeng Zhu, Jennifer N. Durham et al. · Nature Cancer · 2021 · 327 citations · Full text

Nivolumab Convert, Hepatology, Medicine +9

Precision treatment in advanced hepatocellular carcinoma

Xupeng Yang, Chen Yang, Shu Zhang et al. · Cancer Cell · 2024 · 324 citations · Full text

Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma

Liangqing Dong, Lihua Peng, Lijie Ma et al. · Journal of Hepatology · 2019 · 252 citations

Tumor Biology, Heterogeneous Immunogenomic Features, Hepatology +9